Journal of cancer research and therapeutics最新文献

{"title":"Immediate changes in MRI signals after the MRI-guided microwave ablation of malignant liver tumors.","authors":"Jian Yang, Yunying Song, Jiwei Geng, Jikun Zhao, Bin Xiao, Hua Zhao, Zhengyu Lin, Derong Zhao","doi":"10.4103/jcrt.jcrt_1458_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1458_24","url":null,"abstract":"<p><strong>Objective: </strong>To observe the immediate changes in MRI signals after the MRI-guided microwave ablation of malignant liver tumors and to explore the pattern of immediate signal changes post-ablation.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 23 patients with 27 lesions who underwent MRI-guided liver microwave ablation at Baoshan people's Hospital from September 2022 to December 2023. The relationship between the changes in MRI signals and time post-ablation was studied. The first scan was performed immediately after ablation (designated as 0 min) and followed by scans at 3 min, 6 min, 10 min, 15 min, 20 min, and 30 min post-ablation. The signal characteristics that changed in each sequence after each scan were measured and recorded.</p><p><strong>Results: </strong>After ablation, the mean maximum diameter of the high-signal range in 27 T1WI ablation foci varied over a short period of time (0 min: 22.00 mm; at 3 min: 26.58 mm; at 6 min: 26.94 mm; at 10 min: 27.06 mm; at 15 min: 27.12mm; at 20 min: 27.16 mm; and at 30 min: 27.16 mm). The change from 0-10 min was statistically significant (t = -10.326, P < 0.001), whereas the change from 10-30 min was not statistically significant (t = -1.536, P = 0.068). And, the signal intensity increased over time. The signal intensity of the primary lesion remained unchanged while the range decreased. There were minimal differences in the range and intensity changes in the T2-weighted imaging (T2WI) sequence. In diffusion-weighted imaging (DWI), the lesions showed high-signal intensity pre-ablation, but in post-ablation, it exhibited a high-signal surrounding the ablation zone with iso-intense or mixed signals, and the apparent diffusion coefficient (ADC) value increased.</p><p><strong>Conclusion: </strong>The high-signal range observed in the T1WI sequence at the 10th min scan after the ablation completely reflected the true extent of the ablated foci, whereas the low-signal range in the T2WI sequence was stable and unchanged.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"435-441"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study on the safety and efficacy of a robotic-assisted navigation and positioning system in CT-guided percutaneous biopsy of thoracic and abdominal tumors.","authors":"Xiang You, Xiaoli Zhu, Qingjie Chen, Jin Chen, Huihuang Lin, Bingyu Huang, Dongyong Yang, Hongjie Hu, Zhengyu Lin","doi":"10.4103/jcrt.jcrt_1888_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1888_24","url":null,"abstract":"<p><strong>Objective: </strong>To compare the safety, accuracy, and application efficacy of a computed tomography (CT)-guided robotic-assisted navigation system and conventional CT-guided percutaneous puncture biopsy techniques for thoracic and abdominal tumor puncture biopsies.</p><p><strong>Methods: </strong>A total of 140 patients with thoracic or abdominal tumors who were scheduled to undergo CT-guided percutaneous puncture biopsy were randomly assigned to the robotic navigation system puncture group and the traditional step-by-step puncture group. Postoperative tissue specimens and pathological diagnosis results were obtained. The success rate of localization, number of adjustments, localization time, and number of CT scans were used as evaluation indicators. In addition, the surgical safety indicators were observed, and the homogeneity differences between the two groups were compared.</p><p><strong>Results: </strong>The robotic navigation group had significantly higher success rates of localization (84.1% vs. 43.7%), fewer adjustment times (1.51 ± 1.48 vs. 3.51 ± 3.05), and fewer CT scan times (4.99 ± 2.11 vs. 7.11 ± 3.74) than the traditional puncture group (P < 0.05). However, no statistically significant differences were observed in the localization times of chest operation and the occurrence of complications between the two groups.</p><p><strong>Conclusion: </strong>The robotic puncture navigation system improves the success rate of localization and reduces the number of puncture adjustments and CT scans; therefore, it is superior to the traditional step-by-step puncture method.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"389-394"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.","authors":"Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han","doi":"10.4103/jcrt.jcrt_277_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_277_24","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.</p><p><strong>Methods: </strong>Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.</p><p><strong>Results: </strong>Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).</p><p><strong>Conclusion: </strong>The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"425-434"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective review of treatment approach and outcomes for locally advanced head and neck squamous cell cancer.","authors":"Yidi Jin, Hao Jiang, Qian Sun, Feifan Li, Xiaohan Wu, Zhifei Huang","doi":"10.4103/jcrt.jcrt_1332_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1332_24","url":null,"abstract":"<p><strong>Background: </strong>We sought to provide clinicians with important insights into the best treatment plans for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) by examining the treatment trends and outcomes of the disease.</p><p><strong>Methods: </strong>Data pertaining to 158 patients with stage III to IVB LA-HNSCC who received treatment at our hospital from October 2019 to October 2021 were examined in this study. The clinical results of various treatment approaches were compared among the patients.</p><p><strong>Results: </strong>Of the 158 patients, 42 (26.6%) received definitive concurrent chemoradiotherapy (CCRT), 41 (36%) received induction chemotherapy (IC), and 95 (60.1%) underwent surgery. The 1-, 2-, and 3-year survival rates were 84.8%, 70.7%, and 59.3%, respectively, with a median follow-up of 36 months. No discernible difference in overall survival was observed between the CCRT and surgical groups (P = 0.397).</p><p><strong>Conclusions: </strong>The decision regarding definitive CCRT, IC followed by definitive CCRT, surgery followed by adjuvant CCRT, or radiotherapy for patients with LA-HNSCC should be made in consultation with the multidisciplinary team. Furthermore, the decision should take into account the patient's overall health and the diagnosis, stage, developmental tendency, preferences, and prognosis of the disease. The most suitable overall treatment strategy for the patient must be formulated.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"381-388"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.","authors":"Fangjie Ding, Junfeng Zhao, Xue Wu, Xiaoman Liu, Yunxing Yang, Ying Li, Lili Qiao, Yingying Zhang","doi":"10.4103/jcrt.jcrt_1279_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1279_24","url":null,"abstract":"<p><strong>Background: </strong>The necessity of postmastectomy radiotherapy (PMRT) following neoadjuvant chemotherapy (NAC) in patients with ypN0 breast cancer remains a controversial clinical issue. To elucidate this issue, the present study performed a systematic review and meta-analysis, focusing on studies of clinically lymph node-negative patients exhibiting a favorable pathologic response to NAC.</p><p><strong>Materials and methods: </strong>After a comprehensive literature search of PubMed and major oncology congress abstracts, 16 studies that met the inclusion criteria were included. A fixed or random effects model was used to assess the impact of PMRT on the local recurrence rate (LRR) and survival outcomes, where appropriate.</p><p><strong>Results: </strong>The pooled data from ten studies indicated that PMRT significantly reduced the LRR in patients with ypN0 breast cancer (risk ratio [RR], 0.52; 95% confidence interval [CI], 0.41-0.67, P < 0.00001). Moreover, a marginal increase in the overall survival (OS) rates was observed in nine studies (RR, 1.01; 95% CI, 1.00-1.02, P = 0.006), whereas no significant effect on disease-free survival (DFS) was found in six studies (RR, 1.01; 95% CI, 0.95-1.08, P = 0.72).</p><p><strong>Conclusions: </strong>Our findings suggest that PMRT is associated with reduced LRR and slightly improved OS in patients with ypN0 breast cancer. However, prospective studies are needed to provide more evidence and inform clinical decision-making.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"477-482"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances in FGL1/LAG3 for cancer diagnosis and treatment: From basics to clinical practice.","authors":"Keyao Hu, Guiming Zhang, Haitao Niu, Lijiang Sun","doi":"10.4103/jcrt.jcrt_2674_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2674_23","url":null,"abstract":"<p><strong>Abstract: </strong>Fibrinogen-like protein 1 (FGL1), a liver-secreted protein involved in proliferation and metabolism, and lymphocyte activation gene 3 (LAG3), an immune checkpoint receptor expressed on the surfaces of various activated immune cells, play critical roles in tumor immunology. Numerous studies have confirmed that FGL1 acts as a ligand for LAG3 and mediates immune evasion by tumor cells. This review aims to provide a comprehensive summary of the research progress in FGL1/LAG3 in terms of its expression, role in the tumor microenvironment, and clinical application. The expression and regulation of FGL1/LAG3 are influenced by multiple cytokines and signaling pathways. In the tumor microenvironment, FGL1/LAG3 modulates tumor cell proliferation, invasion, and migration through mechanisms such as epithelial-mesenchymal transition, gene methylation, oxygen metabolism, and lipid metabolism. FGL1/LAG3 can serve as a prognostic biomarker, independently or in combination with PD-L1/PD-1, and can be targeted using monoclonal antibodies, bi-specific antibodies, and dual-targeted vaccines to restore the proliferation and activation potential of T cells. Additionally, FGL1/LAG3 has demonstrated therapeutic potential when combined with targeted therapies, radiotherapy, traditional Chinese medicine, and adoptive cell therapy. Overall, FGL1/LAG3 plays a pivotal role in cancer initiation, progression, diagnosis, treatment, and prognosis.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"344-353"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing colorectal cancer diagnosis: The role of tumor-derived serum galanin and haptoglobin as novel biomarkers.","authors":"Ning Yuan, Ren Ren, Dan Li, Xinmei Liang, Xiaochen Pang, Jun Wang, Xiaodong Feng, Zhijun Zhang","doi":"10.4103/jcrt.jcrt_1742_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1742_24","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a widespread and serious global malignancy. This study aimed to investigate the clinical relevance of galanin (GAL) and haptoglobin (HP) as new diagnostic CRC biomarkers.</p><p><strong>Methods: </strong>An enzyme-linked immunosorbent assay was used to determine the GAL and HP levels in the serum of 88 patient with CRC and 88 healthy controls. The carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) contents were quantitatively evaluated via electrochemiluminescence assay. Receiver operating characteristic (ROC) curves were created to identify the diagnostic importance of single and combined CRC detection. The patients' relevant diagnostic and treatment data were collected from their medical records. Statistical analysis methods were employed to examine the relationship between these indicators and the clinical pathological parameters.</p><p><strong>Results: </strong>Patients with CRC exhibited significantly decreased and increased serum GAL and HP levels, respectively, compared with the healthy controls (P < 0.0001 for both). Furthermore, the HP level was positively correlated with tumor T stage (P = 0.0124). The area under the curve (AUC) of the ROC values for GAL and HP was 0.744 and 0.712, respectively, indicating their diagnostic efficiency. The combination of GAL and HP increased the AUC to 0.753, and when both were integrated with CEA and CA19-9, the AUC further increased to 0.893.</p><p><strong>Conclusion: </strong>This study shows that serum GAL and HP can be used as potential noninvasive diagnostic biomarkers for CRC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"417-424"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning model for predicting the RAS oncogene status in colorectal cancer liver metastases.","authors":"Baogen Zhang, Kai Wang, Ting Xu, Haibin Zhu, Kangjie Wang, Jing Wang, Yaoxian Xiang, Xuelei He, Siyu Zhu, Chao An, Dong Yan","doi":"10.4103/jcrt.jcrt_1910_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1910_24","url":null,"abstract":"<p><strong>Background: </strong>To develop a deep learning radiomics (DLR) model based on contrast-enhanced computed tomography (CECT) to assess the rat sarcoma (RAS) oncogene status and predict targeted therapy response in colorectal cancer liver metastases (CRLM).</p><p><strong>Methods: </strong>This multicenter retrospective study comprised 185 CRLM patients who were categorized into three cohorts: training (n = 88), internal test (n = 39), and external test (n = 58). A total of 1126 radiomic features and 2589 DL signatures were extracted from each region of interest in the CECT. Fourteen significant radiomic features associated with RAS mutation were selected. Subsequently, various models (DL-arterial phase (AP), DL-venous phase (VP), AP+VP-DL, radiomics, and DL-R) were developed and validated. The model performance was compared using the area under the receiver operating characteristic (AUROC) curves and the DeLong test. The predictive usefulness of the DL score for progression-free survival and overall survival (OS) was determined.</p><p><strong>Results: </strong>The AP+VP-DL model achieved the highest AUC (0.98), outperforming the radiomics (0.90), DL-AP (0.93), DL-VP (0.87), and DL-R (0.97) models. Significant associations were observed between OS and the carcinoembryonic antigen (CEA), disease control rate (DCR), and DL scores, leading to the development of a DL nomogram. A high-risk RAS mutation status correlated with significantly lower 1-year (88% vs. 96%), 3-year (12% vs. 35%), and 5-year (0% vs. 15%) cumulative survival rates compared to a low-risk status (P = 0.03).</p><p><strong>Conclusions: </strong>The DL model demonstrated satisfactory predictive performance, aiding clinicians in noninvasively predicting the RAS gene status for informed treatment decisions.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"362-370"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal mesenteric metastasis from prostate cancer treated with adjunctive hydrodissection during cryoablation.","authors":"Yufeng Wang, Xiaoguang Li","doi":"10.4103/jcrt.jcrt_1148_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1148_24","url":null,"abstract":"<p><strong>Abstract: </strong>Cryoablation is a safe and promising technique for patients with solid tumors. However, when adjacent to vulnerable structures, appropriate protective measures are necessary while carrying out this procedure. Herein, we present a case of a prostate cancer patient with rectal mesenteric metastasis who underwent cryoablation. The lesion was separated from the rectum by hydrodissection. No grade II-IV adverse events were encountered intraoperatively, and dramatic improvements in the stool were observed. These findings indicate that cryoablation combined with hydrodissection is a safe and reliable treatment method for lesions adjacent to the rectum.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"509-511"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of materia medica in combination with transarterial chemoembolization on inflammatory markers in patients with hepatocellular carcinoma: A systematic review and meta-analysis.","authors":"Chengyang Yu, Yifan Yu, Xiongwen Wang","doi":"10.4103/jcrt.jcrt_1954_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1954_24","url":null,"abstract":"<p><strong>Objectives: </strong>Chinese materia medica (CMM) demonstrates promise in suppressing cancer cell proliferation and metastasis. Cytokines facilitate cellular communication within the tumor microenvironment (TME). This study aimed to examine the influence of integrating CMM with transarterial chemoembolization (TACE) on inflammatory markers and enhancing the TME in hepatocellular carcinoma (HCC) patients.</p><p><strong>Methods: </strong>Articles published between 2006 and 2023 were comprehensively searched from eight databases. The selected studies met the PICOS criteria and primarily consisted of randomized controlled trials (RCTs) that examined the treatment of primary HCC patients with TACE as a standalone therapy or combined with CMM. The outcome measures included inflammatory markers, objective response rate (ORR), alpha-fetoprotein (AFP) levels, and survival rates.</p><p><strong>Results: </strong>The meta-analysis included nine RCTs involving 696 HCC patients: 349 in the TACE + CMM group and 347 in the TACE-only group. The TACE + CMM group demonstrated significantly higher levels of IL-2 (P < 0.00001), IL-12 (P < 0.00001), and IFN-γ (P < 0.00001) and significantly lower levels of IL-6 (P = 0.0007), IL-8 (P < 0.00001), TNF-α (P = 0.01), and AFP (P = 0.0002) compared to the TACE-only group. No significant difference in the C-reactive protein level (P = 0.12) was observed between the two groups. The TACE + CMM group showed a higher ORR (P < 0.0001) than the TACE-only group.</p><p><strong>Conclusions: </strong>Compared to using TACE alone, the integration of CMM with TACE enhanced the modulation of inflammatory markers and the clinical outcomes in patients with HCC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"483-493"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}